Evommune (NYSE:EVMN) CEO Sells $168,916.98 in Stock

Evommune, Inc. (NYSE:EVMN) CEO Luis Pena sold 7,438 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $22.71, for a total transaction of $168,916.98. Following the completion of the sale, the chief executive officer owned 630,458 shares of the company’s stock, valued at approximately $14,317,701.18. This trade represents a 1.17% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Evommune Price Performance

NYSE EVMN traded down $0.72 on Wednesday, hitting $23.53. 1,043,288 shares of the stock were exchanged, compared to its average volume of 453,427. The company’s 50-day moving average price is $23.14 and its two-hundred day moving average price is $22.27. Evommune, Inc. has a 52-week low of $13.89 and a 52-week high of $33.20. The company has a market capitalization of $847.59 million and a price-to-earnings ratio of -2.48.

Evommune (NYSE:EVMN) last released its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.19. Equities analysts predict that Evommune, Inc. will post -2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on EVMN shares. Oppenheimer began coverage on Evommune in a research report on Tuesday, April 7th. They set an “outperform” rating and a $50.00 price objective for the company. Morgan Stanley increased their price target on shares of Evommune from $54.00 to $55.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. Wall Street Zen cut shares of Evommune from a “hold” rating to a “sell” rating in a report on Saturday, June 13th. Clear Str raised shares of Evommune to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Evommune in a research report on Tuesday, May 26th. Three analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $49.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Evommune during the 4th quarter worth about $34,000. Strs Ohio acquired a new stake in shares of Evommune during the 1st quarter valued at about $41,000. The Manufacturers Life Insurance Company bought a new stake in shares of Evommune in the 4th quarter valued at approximately $179,000. XTX Topco Ltd acquired a new position in Evommune in the fourth quarter worth approximately $321,000. Finally, Oxford Asset Management LLP acquired a new position in Evommune in the fourth quarter worth approximately $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.